KR101990096B1 - 알파-시누클레인 항체와 그것의 용도 - Google Patents

알파-시누클레인 항체와 그것의 용도 Download PDF

Info

Publication number
KR101990096B1
KR101990096B1 KR1020157025875A KR20157025875A KR101990096B1 KR 101990096 B1 KR101990096 B1 KR 101990096B1 KR 1020157025875 A KR1020157025875 A KR 1020157025875A KR 20157025875 A KR20157025875 A KR 20157025875A KR 101990096 B1 KR101990096 B1 KR 101990096B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
fragment
syn
alpha
Prior art date
Application number
KR1020157025875A
Other languages
English (en)
Korean (ko)
Other versions
KR20160010402A (ko
Inventor
엘 아그나프 오마르
Original Assignee
유나이티드 아랍에미리트 대학교
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/781,158 external-priority patent/US20140241987A1/en
Application filed by 유나이티드 아랍에미리트 대학교 filed Critical 유나이티드 아랍에미리트 대학교
Publication of KR20160010402A publication Critical patent/KR20160010402A/ko
Application granted granted Critical
Publication of KR101990096B1 publication Critical patent/KR101990096B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
KR1020157025875A 2013-02-28 2014-02-27 알파-시누클레인 항체와 그것의 용도 KR101990096B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/781,158 2013-02-28
US13/781,158 US20140241987A1 (en) 2013-02-28 2013-02-28 Alpha-synuclein antibodies and uses thereof
US14/138,347 2013-12-23
US14/138,347 US9534044B2 (en) 2013-02-28 2013-12-23 Alpha-synuclein antibodies and uses thereof
PCT/IB2014/059287 WO2014132210A1 (fr) 2013-02-28 2014-02-27 Anticorps d'alpha-synucléine et leurs utilisations

Publications (2)

Publication Number Publication Date
KR20160010402A KR20160010402A (ko) 2016-01-27
KR101990096B1 true KR101990096B1 (ko) 2019-06-19

Family

ID=51388371

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157025875A KR101990096B1 (ko) 2013-02-28 2014-02-27 알파-시누클레인 항체와 그것의 용도

Country Status (7)

Country Link
US (2) US9534044B2 (fr)
EP (1) EP2961774B1 (fr)
JP (1) JP6261621B2 (fr)
KR (1) KR101990096B1 (fr)
CN (1) CN105121473B (fr)
HK (1) HK1217107A1 (fr)
WO (1) WO2014132210A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160077112A1 (en) * 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of Misfolded Proteins
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
EP4356967A3 (fr) * 2014-11-14 2024-07-24 United Arab Emirates University Composés destinés à être utilisés en tant qu'agents d'imagerie
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
AU2016270474A1 (en) 2015-06-04 2018-01-04 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
UA124733C2 (uk) * 2016-06-02 2021-11-10 Медімм'Юн Лімітед Антитіло до альфа-синуклеїну
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
WO2018091444A1 (fr) 2016-11-15 2018-05-24 H. Lundbeck A/S Agents, utilisations et procédés pour le traitement d'une synucléinopathie
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110494445B (zh) * 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
EP3567054A4 (fr) * 2017-01-06 2021-03-10 ABL Bio Inc. Anticorps anti-alpha-syn et son utilisation
CA3051839A1 (fr) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Anticorps anti-alpha-synucleine et leurs utilisations
EP3618870A4 (fr) 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania Anticorps monoclonaux contre les fibrilles d'alpha-synucléine
WO2019018607A1 (fr) * 2017-07-20 2019-01-24 Enzo Biochem, Inc. Compositions immunomodulatrices et procédés d'utilisation associés
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
EP3684463A4 (fr) 2017-09-19 2021-06-23 Neuroenhancement Lab, LLC Procédé et appareil de neuro-activation
US20230279085A1 (en) * 2017-11-17 2023-09-07 Abl Bio Inc. ANTIBODIES TO alpha-SYNUCLEIN AND USES THEREOF
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
AU2018385230B2 (en) * 2017-12-14 2022-10-13 Abl Bio Inc. Bispecific antibody to a-syn/IGF1R and use thereof
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020009482A1 (fr) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 Anticorps anti-alpha-synucléine et son utilisation
WO2020056418A1 (fr) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC Système et procédé d'amélioration du sommeil
CA3129501A1 (fr) 2019-02-15 2020-08-20 University Of Southern California Compositions d'anticorps lym-1 et lym-2 et constructions car ameliorees
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
CN117024589A (zh) * 2019-06-14 2023-11-10 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
PE20220646A1 (es) * 2019-07-16 2022-04-28 Univ Washington Anticuerpos anti-grp78 y metodo de uso de los mismos
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
NL2025332B1 (en) 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
AU2021298222A1 (en) * 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies
WO2022060236A1 (fr) * 2020-09-17 2022-03-24 Qatar Foundation For Education, Science And Community Development COMPOSITIONS D'ANTICORPS CIBLANT DES AGRÉGATS D'α-SYNUCLÉINE NON-PHOSPHORYLÉE
CN113912715B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白抗体及其相关产品和应用
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用
CN114853887B (zh) * 2022-03-08 2022-12-20 骏蓦(北京)生物科技有限公司 一种特异性结合α-突触核蛋白的抗体及其应用
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177972A1 (fr) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Molécules de liaison anti-alpha-synucléine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
KR20060135671A (ko) * 2003-11-20 2006-12-29 메디뮨 인코포레이티드 ＥｐｈＡ２ 작동성 모노클로날 항체 및 이의 사용 방법
RU2495882C2 (ru) * 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
GB0716885D0 (en) 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
CN101570575B (zh) * 2008-04-30 2012-02-29 北京市肿瘤防治研究所 Sncg的单克隆抗体及其应用
CA2746778C (fr) * 2008-12-19 2019-04-23 University Of Zurich Auto-anticorps humains anti-alpha-synucleine
WO2011016238A1 (fr) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Anticorps qui se lient spécifiquement à des bêta-oligomères et utilisation de ceux-ci
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
EP2539366B1 (fr) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Anticorps se liant aux protofibrilles et utilisation associée dans des méthodes thérapeutiques et diagnostiques pour la maladie de parkinson, la démence à corps de lewy et d'autres alpha-synucléinopathies
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177972A1 (fr) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Molécules de liaison anti-alpha-synucléine

Also Published As

Publication number Publication date
KR20160010402A (ko) 2016-01-27
EP2961774A1 (fr) 2016-01-06
JP2016511254A (ja) 2016-04-14
US20170190765A1 (en) 2017-07-06
HK1217107A1 (zh) 2016-12-23
JP6261621B2 (ja) 2018-01-17
US10208111B2 (en) 2019-02-19
US20140241984A1 (en) 2014-08-28
CN105121473A (zh) 2015-12-02
EP2961774B1 (fr) 2021-12-29
US9534044B2 (en) 2017-01-03
WO2014132210A1 (fr) 2014-09-04
CN105121473B (zh) 2019-11-12
EP2961774A4 (fr) 2016-10-26

Similar Documents

Publication Publication Date Title
KR101990096B1 (ko) 알파-시누클레인 항체와 그것의 용도
KR102695287B1 (ko) 항-phf-타우 항체 및 이의 용도
CN116410316A (zh) 抗cd47抗体及其用途
NZ738595A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
IL263530B2 (en) Antibodies specific to hyperphosphorylated tau and methods of their use
AU2017219749A1 (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
BR112020009707A2 (pt) anticorpos para a-sinucleína e usos dos mesmos
TW201636371A (zh) 抗甲狀腺素運送蛋白抗體
CA3134785A1 (fr) Anticorps anti-pyroglutamate-amyloide beta et leurs utilisations
US20220298231A1 (en) Novel Molecules for Therapy and Diagnosis
AU2021209746A1 (en) Anti-ANGPTL3 antibody and use thereof
CN111263820A (zh) 抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
US20140241987A1 (en) Alpha-synuclein antibodies and uses thereof
KR102523019B1 (ko) 항-a베타 항체 및 이의 용도
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
US11802149B2 (en) Anti-amyloid beta antibodies and methods of using the same
JP2018508193A (ja) メディンを認識する抗体
WO2022238459A1 (fr) Nouveaux anticorps anti-vegfc humanisés et leurs utilisations
EA045911B1 (ru) АНТИТЕЛА К ПИРОГЛУТАМАТ-β-АМИЛОИДУ И ИХ ПРИМЕНЕНИЕ
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant